Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Ordinary shares, par value NIS 0.10 per share
-
Shares outstanding
-
2,048,819,940
-
Total 13F shares
-
1,114,666
-
Share change
-
-238,784
-
Total reported value
-
$1,750,366
-
Put/Call ratio
-
111%
-
Price per share
-
$1.57
-
Number of holders
-
27
-
Value change
-
-$436,655
-
Number of buys
-
8
-
Number of sells
-
13
Institutional Holders of BioLineRx Ltd. - Ordinary shares, par value NIS 0.10 per share (BLRX) as of Q4 2023
As of 31 Dec 2023,
BioLineRx Ltd. - Ordinary shares, par value NIS 0.10 per share (BLRX) was held by
27 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,114,666 shares.
The largest 10 holders included
MORGAN STANLEY, SUSQUEHANNA INTERNATIONAL GROUP, LLP, Atria Wealth Solutions, Inc., LPL Financial LLC, PVG ASSET MANAGEMENT CORP, Values First Advisors, Inc., ENVESTNET ASSET MANAGEMENT INC, Geneos Wealth Management Inc., Qube Research & Technologies Ltd, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
27
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.